EGFR and non-small cell lung carcinoma: We also look forward to more clinical trial data to verify the results of our subgroup analysis, and more subgroup analysis can be carried out, such as different EGFR mutation sites, etc. Third, the original objective of our study was to explore the efficacy and safety of ICIs in EGFR‐mutated NSCLC who progressed on treatment with EGFR‐TKI.